2型糖尿病の高齢者におけるガンリスクとのグルカゴン様ペプチド1受容体アゴニストの関連

Ying Lu¹, Hao Dai², Huilin Tang^1,3

¹Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.

Obesity (Silver Spring, Md.)

|August 21, 2025

まとめ

2型糖尿病患者の腎臓および子宮内膜がんのリスクを増加させる可能性があります. これらの発見を確認し,潜在的な腫瘍発生リスクを評価するためにさらなる研究が必要である.

科学分野:

内分泌学
腫瘍学
薬用警戒について

背景:

GLP-1RAと癌のリスクとの関連性に関する実際の証拠は限られている.
既存の研究では,ガン発症に関するGLP-1RAの安全性に関する結果が異なっています.

研究の目的:

GLP-1RAと肥満に関連した9種類の癌のリスクを調査する.
GLP- 1RAsを投与した患者とSGLT2阻害剤またはDPP4阻害剤を比較する.

主な方法:

2型糖尿病の癌ナビ患者に対する2013~2020年度のメディケア請求データを使用した.
GLP-1RAイニシアターとSGLT2iおよびDPP4iイニシアターを比較するために,1:1の傾向スコアマッチングを使用した.
様々な癌の危険性比を推定するためにコックスの比例的危険性モデルを適用した.

主要な成果:

GLP- 1RAの使用は,SGLT2阻害剤と比較して,腎臓がんのリスクが著しく増加した (HR,1. 43 [1. 06-1.92]).
GLP- 1RAの使用は,DPP4阻害剤と比較して,子宮内膜がんのリスクが著しく上昇した (HR,1. 55 [1. 01-2.37]).
GLP- 1RAとSGLT2iまたはDPP4iの使用者の間で,全体的ながんリスクの有意な違いは観察されなかった.

結論:

特に腎臓と子宮内膜がんのリスクが増加する可能性があります.
GLP- 1RAsに関連したこれらの潜在的な腫瘍発生リスクを検証するために,さらなる調査が必要である.

キーワード:

GLP-1受容体アゴニスト癌についてディペプチジルペプチダゼ-4 阻害剤ナトリウム・グルコース・コトランスポーター−2阻害剤 2 型糖尿病

さらに関連する動画

12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

12.7K

05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

348

関連する概念動画

01:24

Glucagon-like Receptor Agonists

416

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

416

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

291

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

291

01:15

Hypoglycemia and Glucagon

334

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

334

01:06

Oral Hypoglycemic Agents: Glinides

257

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

257

01:19

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...

01:23

Dipeptidyl Peptidase 4 Inhibitors

256

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

256

関連する実験動画